NeoGenomics Inc (NEO)vsWaters Corporation (WAT)
NEO
NeoGenomics Inc
$10.90
-3.63%
HEALTHCARE · Cap: $1.37B
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 405% more annual revenue ($3.77B vs $745.97M). WAT leads profitability with a 11.9% profit margin vs -13.3%. WAT appears more attractively valued with a PEG of 1.60. NEO earns a higher WallStSmart Score of 51/100 (C-).
NEO
Buy51
out of 100
Grade: C-
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$51.46
Current Price
$10.90
$40.56 discount
Margin of Safety
-84.6%
Fair Value
$178.29
Current Price
$365.36
$187.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.1% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Market Cap, Piotroski F-Score.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
NEO profiles as a turnaround stock while WAT is a growth play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.80 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
NEO generates stronger free cash flow (-13M), providing more financial flexibility.
Bottom Line
NEO scores higher overall (51/100 vs 50/100) and 11.1% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?